ImmunityBio Reports Impressive Revenue Growth

By Chris Stiles • Thursday, April 09 11:18 • Permanent Link

ImmunityBio said preliminary net product revenue for the quarter ended March 31, 2026 reached about $44.2 million, up 168% from the same quarter a year earlier and 15% higher than the $38.3 million reported in the prior quarter.

For full-year 2025, net product revenue totaled $113 million, a 700% increase from full-year 2024.

The company said ANKTIVA unit sales volume rose 168% in Q1 2026 versus Q1 2025, and that the product is now approved or authorized in five regulatory jurisdictions covering about 34 countries.

ImmunityBio ended the quarter with $380.9 million in cash, cash equivalents and marketable securities.

On the clinical side, the company said its pivotal BCG-naïve NMIBC CIS trial, QUILT-2.005, is fully enrolled, with the independent data monitoring committee confirming no additional enrollment is needed and adequate statistical power. The company also said its supplemental BLA submission remains on track for 2026.

The NCCN updated its clinical practice guidelines in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease, category 2A. Today the company's shares have moved -8.55% to a price of $7.38. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.